Vistagen Therapeutics Management
Management criteria checks 1/4
Vistagen Therapeutics' CEO is Shawn Singh, appointed in Aug 2009, has a tenure of 15.25 years. total yearly compensation is $947.92K, comprised of 65.7% salary and 34.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $94.71K. The average tenure of the management team and the board of directors is 1.7 years and 8.7 years respectively.
Key information
Shawn Singh
Chief executive officer
US$947.9k
Total compensation
| CEO salary percentage | 65.7% |
| CEO tenure | 15.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.7yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis
Sep 08VistaGen drops 80% as late-stage study for anxiety therapy fails
Jul 22Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation
Apr 10
VistaGen Therapeutics added to Russell 2000 Index
Jun 16VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business
Jun 07VistaGen initiates late-stage trial of PH94B in social anxiety disorder
May 26VistaGen names new chief commercial officer
May 04How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?
Feb 16
VistaGen Therapeutics regains Nasdaq listing compliance
Jan 06VistaGen Therapeutics slumps in after hours trade on underwritten public offering
Dec 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$40m |
| Jun 30 2024 | n/a | n/a | -US$33m |
| Mar 31 2024 | US$948k | US$623k | -US$29m |
| Dec 31 2023 | n/a | n/a | -US$32m |
| Sep 30 2023 | n/a | n/a | -US$35m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | US$600k | US$600k | -US$59m |
| Dec 31 2022 | n/a | n/a | -US$64m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$60m |
| Mar 31 2022 | US$1m | US$563k | -US$49m |
| Dec 31 2021 | n/a | n/a | -US$62m |
| Sep 30 2021 | n/a | n/a | -US$56m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | US$1m | US$511k | -US$42m |
| Dec 31 2020 | n/a | n/a | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | US$934k | US$498k | -US$22m |
| Dec 31 2019 | n/a | n/a | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | US$951k | US$466k | -US$26m |
| Dec 31 2018 | n/a | n/a | -US$24m |
| Sep 30 2018 | n/a | n/a | -US$20m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | US$1m | US$425k | -US$16m |
Compensation vs Market: Shawn's total compensation ($USD947.92K) is above average for companies of similar size in the US market ($USD648.89K).
Compensation vs Earnings: Shawn's compensation has increased whilst the company is unprofitable.
CEO
Shawn Singh (61 yo)
15.3yrs
Tenure
US$947,917
Compensation
Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$947.92k | 0.12% $ 94.7k | |
| VP & Chief Financial Officer | 1.3yrs | US$434.19k | 0.013% $ 10.9k | |
| Chief Operating Officer | 2yrs | US$568.44k | 0.0099% $ 8.1k | |
| Chief Corporate Development Officer & General Counsel | 2.5yrs | US$675.00k | 0.061% $ 49.9k | |
| Senior Vice President of Investor Relations | 1.6yrs | US$479.99k | no data | |
| Senior Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Development Operations | no data | no data | no data | |
| Senior VP and Head of Chemistry | 3.8yrs | no data | no data | |
| Senior Vice President of Corporate Strategy & Capital Markets | 1.6yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs & Pharmacovigilance | 1.3yrs | no data | no data | |
| Senior Vice President of Translational Neuroscience | less than a year | no data | no data | |
| VP, Associate General Counsel & Secretary | 1.8yrs | no data | no data |
1.7yrs
Average Tenure
56yo
Average Age
Experienced Management: VTGN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.8yrs | US$947.92k | 0.12% $ 94.7k | |
| Independent Director | 24.8yrs | US$129.37k | 0.0069% $ 5.6k | |
| Independent Director | 8.7yrs | US$128.12k | 0.049% $ 40.3k | |
| Chairman of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Member of Clinical & Regulatory Advisory Board | 8.7yrs | no data | no data | |
| Member of Clinical & Regulatory Advisory Board | 9.1yrs | no data | no data | |
| Member of CNS Clinical and Regulatory Advisory Board | 6.1yrs | no data | no data | |
| Independent Chair of the Board | 3.3yrs | US$185.62k | 0% $ 0 | |
| Member of Clinical & Regulatory Advisory Board | 7.3yrs | no data | no data | |
| Member of Clinical & Regulatory Advisory Board | 9.8yrs | no data | no data | |
| Independent Director | 3.3yrs | US$128.12k | 0% $ 0 | |
| Member of Clinical & Regulatory Advisory Board | 8.7yrs | no data | no data |
8.7yrs
Average Tenure
64yo
Average Age
Experienced Board: VTGN's board of directors are considered experienced (8.7 years average tenure).